Guidelines for the use of MS Contin tablets in the management of cancer pain.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 1758825.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
MS Contin (controlled-release oral morphine) has been successfully used to treat moderate to severe pain associated with cancer. The indication for administering MS Contin is not a poor prognosis, but rather pain requiring repeated dosing with potent opioids over periods of more than a few days. Individualization of analgesic dosage to each patient's needs can provide excellent relief of pain in most patients but require selection of the right analgesic in the right dose at the right intervals.
Medical subject headings
- Morphine
- Neoplasms
- Pain